HLCS: Helicos BioScienc - $0.53, $42.30M, 0.01 (1.92%)

Helicos BioSciences Corporation, a life sciences company, focuses on genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets. The company’s products are based on its proprietary True Single Molecule Sequencing technology, which enables the analysis of genetic material by directly sequencing single molecules of DNA or single DNA copies of RNA. Its Helicos genetic analysis platform consists of HeliScope single molecule sequencer; HeliScope analysis engine, an image analysis computer tower; associated reagents, which are chemicals used in the sequencing process; and disposable supplies. The company’s Helicos genetic analysis system is used for various applications in the areas of studying the human genome, disease association studies, cancer research, pharmaceutical research and development, infectious diseases, autoimmune conditions, clinical diagnostics, and agricultural research. Its customers include genome sequencing centers, biotechnology and pharmaceutical companies, and academic medical centers and research institutions in the United States and Canada. The company was formerly known as Newco LS6, Inc. and changed its name to Helicos BioSciences Corporation in November 2003. Helicos BioSciences Corporation was founded in 2003 and is headquartered in Cambridge, Massachusetts.